Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of “Reduce” from Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been given a consensus recommendation of “Reduce” by the twelve ratings firms that are presently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $8.20.

FULC has been the topic of a number of analyst reports. JPMorgan Chase & Co. cut shares of Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating in a research note on Wednesday, June 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Friday, July 17th. Truist Financial downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a report on Tuesday, June 2nd. Cantor Fitzgerald lowered shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Finally, HC Wainwright cut shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 price objective for the company. in a report on Tuesday, June 2nd.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ:FULC opened at $3.85 on Tuesday. Fulcrum Therapeutics has a twelve month low of $2.83 and a twelve month high of $15.74. The company’s 50 day moving average is $3.75 and its 200 day moving average is $5.69. The company has a market cap of $293.75 million, a PE ratio of -3.18 and a beta of 2.59.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). Equities research analysts predict that Fulcrum Therapeutics will post -0.69 earnings per share for the current fiscal year.

Insider Activity at Fulcrum Therapeutics

In other news, Director Alan Ezekowitz sold 18,000 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $3.65, for a total transaction of $65,700.00. Following the sale, the director directly owned 10,927 shares in the company, valued at $39,883.55. This trade represents a 62.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Quarry LP purchased a new stake in shares of Fulcrum Therapeutics in the third quarter valued at approximately $35,000. Meeder Asset Management Inc. acquired a new stake in Fulcrum Therapeutics in the 4th quarter valued at $39,000. Summit Securities Group LLC acquired a new stake in Fulcrum Therapeutics in the 1st quarter valued at $53,000. The Manufacturers Life Insurance Company purchased a new stake in Fulcrum Therapeutics in the 2nd quarter worth $61,000. Finally, Russell Investments Group Ltd. increased its holdings in Fulcrum Therapeutics by 4,209.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock worth $64,000 after acquiring an additional 9,092 shares in the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.